Immix Biopharma (IMMX) Common Equity (2020 - 2026)
Immix Biopharma's Common Equity was $228.92 million in Q2 2026, compared with $4.65 million a year earlier and up 171.3% from the prior quarter.
Powered by 
Analysis
Immix Biopharma (IMMX) Common Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Immix Biopharma came in at $93.8 million, up 607.8% from FY2024.
- In earlier years, Common Equity was $13.25 million in FY2024 (-18.2%), $16.2 million in FY2023 (+23.1%), $13.16 million in FY2022 (-26.8%) and $17.99 million in FY2021.
- The Q2 2026 figure marks the highest quarterly Common Equity in data going back to Q4 2020.
- Compared with a year earlier, Common Equity was higher in two of the last seven quarters, with growth averaging 165.7%.
- The best year-over-year quarter for Common Equity over five years was Q1 2026 (growth of 779.4%); the worst was Q2 2025 (a decline of 80.5%).
- Per Business Quant data, IMMX's Common Equity in the three quarters before Q2 2026 was $84.36 million (Q1 2026), $93.8 million (Q4 2025) and $8.26 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Immix Biopharma | 820.51 Mn | 820.51 Mn | - | 228.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 228.92 Mn |
| Mar 31, 2026 | 84.36 Mn |
| Dec 31, 2025 | 93.80 Mn |
| Sep 30, 2025 | 8.26 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Mar 31, 2025 | 9.59 Mn |
| Dec 31, 2024 | 13.25 Mn |
| Sep 30, 2024 | 17.55 Mn |
| Jun 30, 2024 | 23.89 Mn |
| Mar 31, 2024 | 27.63 Mn |
| Dec 31, 2023 | 16.20 Mn |
| Sep 30, 2023 | 19.65 Mn |
| Jun 30, 2023 | 13.17 Mn |
| Mar 31, 2023 | 11.74 Mn |
| Dec 31, 2022 | 13.16 Mn |
| Sep 30, 2022 | 16.75 Mn |
| Jun 30, 2022 | 18.11 Mn |
| Mar 31, 2022 | 19.65 Mn |
| Dec 31, 2021 | 17.99 Mn |
| Sep 30, 2021 | -6.20 Mn |
API Access
Immix Biopharma Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=IMMX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "IMMX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=IMMX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();